How Insight Molecular Diagnostics (IMDX) Story Is Shifting With New Funding And GraftAssureDx Catalyst [Yahoo! Finance]
Insight Molecular Diagnostics Inc. (IMDX)
Company Research
Source: Yahoo! Finance
Insight Molecular Diagnostics is back in focus after analysts updated their price target, with some now pointing to US$12 alongside a refreshed fair value estimate of US$8.33, previously US$7.00. That shift is being linked to views on the recent US$26m offering, funding visibility around upcoming milestones, and expectations for the planned FDA submission for GraftAssureDx, even as others flag the associated risks. As you read on, you will see how this evolving narrative might shape sentiment around the stock over time. Stay updated as the Fair Value for Insight Molecular Diagnostics shifts by adding it to your watchlist or portfolio . Alternatively, explore our Community to discover new perspectives on Insight Molecular Diagnostics. What Wall Street Has Been Saying ?? Bullish Takeaways Lake Street lifted its price target on Insight Molecular Diagnostics to US$12 from US$8, signaling a higher assessed value for the shares based on its latest review. The firm highlights the
Show less
Read more
Impact Snapshot
Event Time:
IMDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMDX alerts
High impacting Insight Molecular Diagnostics Inc. news events
Weekly update
A roundup of the hottest topics
IMDX
News
- Insight Molecular Diagnostics Completes Key Milestones Advancing GraftAssureDx Toward FDA Submission [Yahoo! Finance]Yahoo! Finance
- Insight Molecular Diagnostics Completes Key Milestones Advancing GraftAssureDx Toward FDA SubmissionGlobeNewswire
- Oncocyte (NASDAQ:IMDX) had its price target raised by analysts at Lake Street Capital from $8.00 to $12.00. They now have a "buy" rating on the stock.MarketBeat
- iMDx Announces $26.0 Million Registered Direct OfferingGlobeNewswire
- Insight ‘congratulated' STAR working group on organ health testing paper [Yahoo! Finance]Yahoo! Finance
IMDX
Sec Filings
- 2/26/26 - Form 8-K
- 2/12/26 - Form SCHEDULE
- 2/12/26 - Form 4
- IMDX's page on the SEC website